Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum

Business Wire February 3, 2015

Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy

GlobeNewswire February 3, 2015

Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference

GlobeNewswire February 2, 2015

Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum

Business Wire January 29, 2015

Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day

GlobeNewswire January 27, 2015

Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer

GlobeNewswire January 7, 2015

Marinus Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

GlobeNewswire December 3, 2014

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2014 Financial Results

GlobeNewswire November 13, 2014

Marinus Pharmaceuticals to Present at the Stifel Healthcare Conference

GlobeNewswire November 11, 2014

Marinus Pharmaceuticals, Inc. to Present at the 21st Annual BioCentury Newsmakers Conference on Friday, September 26, 2014

GlobeNewswire September 25, 2014

Marinus Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option in Public Offering of Common Stock

GlobeNewswire September 2, 2014

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Ring The NASDAQ Stock Market Opening Bell

GlobeNewswire August 25, 2014

Marinus Pharmaceuticals, Inc. to Ring the Opening Bell of the NASDAQ Stock Market

GlobeNewswire August 25, 2014

Marinus Pharmaceuticals, Inc. Enters Into Use Agreement With CyDex Pharmaceuticals, Inc. for Use of Captisol(R) for Ganaxolone IV

GlobeNewswire August 12, 2014

Marinus Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

GlobeNewswire July 31, 2014